Back to Browse Journals » Patient Preference and Adherence » Volume 5

Efficacy and safety of ultra-low-dose Vagifem (10 mcg)

Authors Chollet JA

Published Date November 2011 Volume 2011:5 Pages 571—574

DOI http://dx.doi.org/10.2147/PPA.S22940

Published 11 November 2011

Janet A Chollet1,2
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 2Pear Tree Pharmaceuticals, Waltham, MA, USA

Abstract: Vulvovaginal atrophy [VVA] is defined as inflammation of the vaginal epithelium due to atrophy secondary to decreased levels of circulating estrogen. There is currently only one approved method for the treatment of VVA, and that is the administration of exogenous estrogens. Overall, the ideal VVA treatment must have benefits, minimize risks, and enhance compliance in the patient while optimizing cost-effectiveness. Unfortunately, of the approximate 25% of symptomatic women that are thought to seek medical help, the proportion that receives hormone therapy may be small and its duration of use is short. Women have been very reluctant to take hormone therapy due to widely publicized results of the risks associated with hormone therapy. Thus, while menopausal hormone therapy was once accepted as the ideal approach for optimizing changes associated with menopause, prospective randomized clinical trials have challenged that view and have led to a marked decrease in the use of such therapy and increased search for low-dose therapies. This article will highlight the efficacy and safety of recently FDA-approved Vagifem (10 mcg) in treatment of VVA.

Keywords: vulvovaginal atrophy, estradiol, menopause

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Update on alternative therapies for vulvovaginal atrophy

Chollet J

Patient Preference and Adherence 2011, 5:533-536

Published Date: 28 October 2011

Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

The ubiquitin–proteasome system as a molecular target in solid tumors: an update on bortezomib

A Milano, F Perri, F Caponigro

OncoTargets and Therapy 2009, 2:171-178

Published Date: 30 June 2009

Palliative treatment of malignant ascites: profile of catumaxomab

Lila Ammouri, Eric E Prommer

Biologics: Targets and Therapy 2010, 4:103-110

Published Date: 14 May 2010

Moyamoya disease with neuro-ophthalmic manifestations: a rare case report

Dipankar Das, Sanjeev Kumar Handique, Harsha Bhattacharjee, et al

Eye and Brain 2010, 2:63-65

Published Date: 20 May 2010

Update on the management of Dupuytren’s contracture

Linda Vi, David B O’Gorman, Bing Siang Gan

Orthopedic Research and Reviews 2010, 2:35-43

Published Date: 31 August 2010

Update on alternative therapies for vulvovaginal atrophy

Chollet J

Patient Preference and Adherence 2011, 5:533-536

Published Date: 28 October 2011

Dormancy in breast cancer

Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, Neubauer H

Breast Cancer: Targets and Therapy 2012, 4:183-191

Published Date: 5 December 2012